8-KAcquisitions & DispositionsMaterial AgreementsFinancial Events+1

ABBOTT LABORATORIES 8-K Report, Material Agreement (Oct 3, 2017)

Filed October 3, 2017For Securities:ABT

Summary

This 8-K filing by Abbott Laboratories (ABT) announces the successful completion of its acquisition of Alere Inc. on October 3, 2017. The transaction, initially announced in January 2016, was finalized through a merger where Alere became a subsidiary of Abbott. Each Alere shareholder received $51.00 in cash per share, and outstanding Alere stock options and restricted stock units were settled in cash as well. This strategic acquisition significantly expands Abbott's diagnostics business, a key growth area for the company. The filing also details the financing for this approximately $4.6 billion acquisition. Abbott secured $2.8 billion through a Term Loan Agreement and an additional $1.7 billion via its Revolving Credit Agreement. This indicates a substantial increase in debt to fund the acquisition, which investors should consider when evaluating the company's leverage and financial flexibility going forward. The completion of this deal marks a significant milestone for Abbott, aiming to enhance its market position in the diagnostics sector.

Key Highlights

  • 1Abbott Laboratories has successfully completed the acquisition of Alere Inc. as of October 3, 2017.
  • 2The acquisition was effected through a merger, with Alere becoming a subsidiary of Abbott.
  • 3Alere shareholders received $51.00 in cash per share, totaling approximately $4.5 billion for outstanding shares.
  • 4Outstanding Alere stock options and restricted stock units were also settled in cash, amounting to approximately $100 million.
  • 5The total aggregate consideration paid for the acquisition was approximately $4.6 billion, excluding transaction fees.
  • 6Abbott financed the acquisition through a $2.8 billion Term Loan Agreement and a $1.7 billion borrowing under its Revolving Credit Agreement.
  • 7The acquisition is expected to bolster Abbott's presence and capabilities in the diagnostics market.

Frequently Asked Questions

This 8-K filing announces the completion of Abbott Laboratories' acquisition of Alere Inc. It details the terms of the merger, the cash consideration paid to Alere shareholders, and the financing arrangements undertaken by Abbott to fund the transaction.

Abbott paid approximately $4.6 billion in total for Alere. This amount includes $4.5 billion for Alere shares and $100 million for Alere stock options and restricted stock units. The acquisition was financed through $2.8 billion borrowed under a Term Loan Agreement and $1.7 billion drawn from Abbott's Revolving Credit Agreement.

The acquisition of Alere is strategically important for Abbott as it significantly expands its diagnostics business. Alere is a global leader in rapid diagnostics, and this integration is expected to strengthen Abbott's position in a key growth area within the healthcare industry.

The acquisition of Alere Inc. by Abbott Laboratories officially closed on October 3, 2017.